Interferon alfa-2a in recurrent metastatic hemangiopericytoma.
Lackner
Herwig
H
Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescence Medicine, Karl-Franzens-University, Graz, Austria.
Urban
Christian
C
Dornbusch
Hans Jürgen
HJ
Schwinger
Wolfgang
W
Kerbl
Reinhold
R
Sovinz
Petra
P
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000628:therapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy / Q000379:methods; D019583:Dose Fractionation, Radiation; D006393:Hemangiopericytoma / Q000188:drug therapy* / Q000556:secondary* / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy*; D019635:Neurosurgical Procedures; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation / Q000379:methods; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013792:Thalidomide